SCHEMBL3017766

SCHEMBL3017766

COc1ccccc1-c1csc(N2CCC(S(=O)(=O)c3ccc(CBr)cc3)CC2)n1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.44
SMN1; SMN2 Q16637 3/20 0.41
SPHK2 Q9NRA0 1/20 0.40
SPHK1 Q9NYA1 1/20 0.40
MAPT P10636 3/20 0.40
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
REV1 Q9UBZ9 1/20 0.39
RECQL P46063 2/20 0.39
USP2 O75604 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM1A O60341 1/20 0.38
UCHL1 P09936 1/20 0.38
USP30 Q70CQ3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007269 0.90 AR (0.46) ARSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL3010419 0.89 MAPT (0.52) ARSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL3011242 0.89 AR (0.47) ARSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL3016521 0.89 AR (0.54) ARSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL3002511 0.89 AR (0.46) ARSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL3009715 0.89 REV1 (0.51) ARSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL3010988 0.88 AR (0.46) ARSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL3007187 0.88 SMN1; SMN2 (0.42) ARSMN1; SMN2SPHK2SPHK1MAPT
SCHEMBL3001893 0.86 AR (0.45) ARSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL3004385 0.86 AR (0.48) ARSMN1; SMN2MAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885SMN1; SMN2 1/4885SPHK2 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.